NO20035209L - Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren samt anvendelse derav og farmasoytisk preparat - Google Patents

Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren samt anvendelse derav og farmasoytisk preparat

Info

Publication number
NO20035209L
NO20035209L NO20035209A NO20035209A NO20035209L NO 20035209 L NO20035209 L NO 20035209L NO 20035209 A NO20035209 A NO 20035209A NO 20035209 A NO20035209 A NO 20035209A NO 20035209 L NO20035209 L NO 20035209L
Authority
NO
Norway
Prior art keywords
hppar
oxazole
pharmaceutical preparations
alpha receptor
thiazole derivative
Prior art date
Application number
NO20035209A
Other languages
English (en)
Norwegian (no)
Other versions
NO20035209D0 (no
Inventor
Francoise Jeanne Gellibert
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20035209D0 publication Critical patent/NO20035209D0/no
Publication of NO20035209L publication Critical patent/NO20035209L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20035209A 2001-05-31 2003-11-24 Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren samt anvendelse derav og farmasoytisk preparat NO20035209L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113231.5A GB0113231D0 (en) 2001-05-31 2001-05-31 Chemical compounds
PCT/EP2002/005886 WO2002096895A1 (en) 2001-05-31 2002-05-29 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor

Publications (2)

Publication Number Publication Date
NO20035209D0 NO20035209D0 (no) 2003-11-24
NO20035209L true NO20035209L (no) 2004-01-27

Family

ID=9915636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035209A NO20035209L (no) 2001-05-31 2003-11-24 Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren samt anvendelse derav og farmasoytisk preparat

Country Status (28)

Country Link
US (1) US7157479B2 (cg-RX-API-DMAC7.html)
EP (1) EP1399430B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532267A (cg-RX-API-DMAC7.html)
KR (1) KR100859591B1 (cg-RX-API-DMAC7.html)
CN (1) CN1307166C (cg-RX-API-DMAC7.html)
AR (1) AR034051A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002317765B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209785A (cg-RX-API-DMAC7.html)
CA (1) CA2448205A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540297A2 (cg-RX-API-DMAC7.html)
CY (1) CY1107206T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033252A3 (cg-RX-API-DMAC7.html)
DE (1) DE60223805T2 (cg-RX-API-DMAC7.html)
DK (1) DK1399430T3 (cg-RX-API-DMAC7.html)
ES (1) ES2296965T3 (cg-RX-API-DMAC7.html)
GB (1) GB0113231D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0400043A3 (cg-RX-API-DMAC7.html)
IL (1) IL158929A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03011032A (cg-RX-API-DMAC7.html)
MY (1) MY132656A (cg-RX-API-DMAC7.html)
NO (1) NO20035209L (cg-RX-API-DMAC7.html)
NZ (1) NZ529754A (cg-RX-API-DMAC7.html)
PL (1) PL367248A1 (cg-RX-API-DMAC7.html)
PT (1) PT1399430E (cg-RX-API-DMAC7.html)
SI (1) SI1399430T1 (cg-RX-API-DMAC7.html)
TW (1) TWI245760B (cg-RX-API-DMAC7.html)
WO (1) WO2002096895A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200309095B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0323702D0 (en) * 2003-10-09 2003-11-12 Smithkline Beecham Corp Chemical compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
JP5357894B2 (ja) * 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
CN110803996B (zh) * 2019-11-13 2022-01-11 台州市创源工业技术有限公司 一种羟基苄胺的合成方法
CN116511225B (zh) * 2023-03-30 2025-09-23 江南大学 一种油酸基des液体及其制备方法和它在厌氧发酵液高效浓缩中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
NZ515087A (en) * 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2448205A1 (en) 2002-12-05
WO2002096895A1 (en) 2002-12-05
DE60223805D1 (de) 2008-01-10
HUP0400043A2 (hu) 2004-04-28
ES2296965T3 (es) 2008-05-01
US20050070517A1 (en) 2005-03-31
KR20040007632A (ko) 2004-01-24
CO5540297A2 (es) 2005-07-29
HK1064367A1 (en) 2005-01-28
AU2002317765B2 (en) 2005-02-03
EP1399430A1 (en) 2004-03-24
CN1307166C (zh) 2007-03-28
GB0113231D0 (en) 2001-07-25
CY1107206T1 (el) 2012-11-21
DE60223805T2 (de) 2008-10-30
JP2004532267A (ja) 2004-10-21
MY132656A (en) 2007-10-31
EP1399430B1 (en) 2007-11-28
CN1633421A (zh) 2005-06-29
CZ20033252A3 (en) 2004-03-17
ZA200309095B (en) 2005-02-21
NO20035209D0 (no) 2003-11-24
TWI245760B (en) 2005-12-21
PL367248A1 (en) 2005-02-21
SI1399430T1 (sl) 2008-04-30
DK1399430T3 (da) 2008-03-25
IL158929A0 (en) 2004-05-12
AR034051A1 (es) 2004-01-21
PT1399430E (pt) 2008-02-19
KR100859591B1 (ko) 2008-09-23
BR0209785A (pt) 2004-06-01
HUP0400043A3 (en) 2008-03-28
US7157479B2 (en) 2007-01-02
MXPA03011032A (es) 2004-03-19
NZ529754A (en) 2005-12-23

Similar Documents

Publication Publication Date Title
NO20016078D0 (no) Tiazol- og oksazol-derivater samt farmasöytisk anvendelse derav
NO20022895L (no) Fremgangsmåter for fremstilling av karotenoider og for fremstilling av fôrmaterialer
DE60010333D1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
NO20042694L (no) 17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater
NO329884B1 (no) Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20041921D0 (no) Peroksisom proliferator-aktivert reseptorligand og fremgangsmate for fremstilling av denne
NO20001648D0 (no) FremgangsmÕter og mellomprodukter for fremstilling av anti- cancer forbindelser
NO20030844D0 (no) Fremgangsmåte for fremstilling av N-aryl-antranilinsyrer og derivater derav
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
ATE405260T1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20055652D0 (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
DK1226131T3 (da) Isoxazolcarboxamidderivater
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
NO20021124L (no) Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor
NO20035209D0 (no) Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren
DE60310750D1 (de) Einheit zum überführen und zum einstellen der zwischenräume von gegenständen
NO20025069D0 (no) Ny stabil krystall av tiazolidindionderivat og fremgangsmÕte for fremstilling av det samme
NO20054535D0 (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
NO20052859D0 (no) Fremgangsmate for fremstilling av resperidon og intermediater derav
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
NO20020308L (no) Fremgangsmåte for fremstilling av epotilon B og derivater derav samt mellomprodukter for fremgangsmåten
NO20014610D0 (no) Måling og styring av strömmen av flytbare materialer
FI20021762A0 (fi) Uusia terapeuttisia aineita ja valmisteita

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application